Blood-based microRNA profiling in patients with cardiac amyloidosis

Anselm A. Derda1,2, Angelika Pfanne1, Christian Bär1, Katharina Schimmel1, Peter J. Kennel3,4, Ke Xiao1, P. Christian Schulze3,5, Johann Bauersachs2,6, Thomas Thum1,2,6,7*

1 Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Hannover, Germany, 2 Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany, 3 Division of Cardiology, Columbia University Medical Center, New York, New York, United States of America, 4 Department of Medicine, Weill Cornell Medicine, New York, New York, United States of America, 5 Department of Internal Medicine I, Division of Cardiology, Pneumology, Angiology and Intensive Medical Care, University Hospital Jena, Friedrich-Schiller-University Jena, Germany, 6 Excellence Cluster REBIRTH, Hannover Medical School, Hannover, Germany, 7 Imperial College London, NHLI London, United Kingdom

* thum.thomashannover.de

Abstract

Introduction
Amyloidosis is caused by dysregulation of protein folding resulting in systemic or organ specific amyloid aggregation. When affecting the heart, amyloidosis can cause severe heart failure, which is associated with a high morbidity and mortality. Different subtypes of cardiac amyloidosis exist e.g. transthyretin cardiac amyloidosis and senile cardiac amyloidosis. Today, diagnostics is primarily based on cardiac biopsies and no clinically used circulating blood-based biomarkers existing. Therefore, our aim was to identify circulating microRNAs in patients with different forms of amyloidosis.

Methods
Blood was collected from healthy subjects (n = 10), patients with reduced ejection fraction (EF < 35%; n = 10), patients affected by transthyretin cardiac amyloidosis (n = 13) as well as senile cardiac amyloidosis (n = 11). After performing TaqMan array profiling, promising candidates, in particular miR-99a-5p, miR-122-5p, miR-27a-3p, miR-221-3p, miR-1180-3p, miR-155-5p, miR-339-3p, miR-574-3p, miR-342-3p and miR-329-3p were validated via quantitative real time PCR.

Results
The validation experiments revealed a significant upregulation of miR-339-3p in patients affected with senile cardiac amyloidosis compared to controls. This corresponded to the array profiling results. In contrast, there was no deregulation in the other patient groups.
Conclusion

MiR-339-3p was increased in blood of patients with senile cardiac amyloidosis. Therefore, miR-339-3p is a potential candidate as biomarker for senile cardiac amyloidosis in future studies. Larger patient cohorts should be investigated.

Introduction

Amyloidosis is a rare and very heterogeneous disease, which can affect several human organs. Pathophysiologic amyloidosis is caused by misfolding of non-soluble proteins, which deposit in an extracellular manner. When affecting the heart, cardiac amyloidosis can lead to cardiac hypertrophy [1,2]. The most common type in the cardiac form is induced by light chain immunoglobulins (AL amyloidosis). In general, the AL type manifests systemically affecting also e.g. the liver or kidney. Another form of this disease is the transthyretin type amyloidosis also called ATTR amyloidosis. A different type affecting mainly men older than 70 years is the wild-type ATTR amyloidosis also named senile cardiac amyloidosis (SCA) [3]. For diagnosis of amyloidosis, cardiac biopsy and echocardiography are used. Until now, there is not any specific biomarker in blood known [3,4].

MicroRNAs (miR’s, miRNAs) are small ribonucleic acids about 20 nucleotides. As important regulators they orchestrate post-transcriptionally gene-expression and are therefore involved in cell differentiation processes [5]. In cardiac diseases they are important players in pathologic processes like e.g. cardiac fibrosis and hypertrophy [6]. Therefore, microRNAs can be used as therapeutic targets. More and above, microRNAs circulating in the blood are used as biomarkers for example in Takotsubo syndrome or Hypertrophic cardiomyopathy [7,8]. The aim of our study was to find specific blood-based microRNAs in serum of patients with different forms of cardiac amyloidosis.

Materials and methods

Study population

All patients including control and heart failure individuals were recruited at the Columbia University Medical Center in New York. All patients gave written informed consent to participate in the study, which was conducted in accordance with the protocol approved by the Institutional Review Board at Columbia University Medical Center. The diagnosis of different types of amyloidosis was defined by myocardial biopsy and echocardiography. In the heart failure group (HF) only patients with an ejection fraction (EF) < 35% and without amyloidosis or other genetic diseases were included.

RNA isolation from patient blood samples

To obtain liquid supernatant by separating the corpuscular components, the serum samples were centrifuged for 10 minutes at 2000 x g at room temperature. Afterwards the supernatant was stored at -80°C. The miRNeasy Mini Kit (Qiagen) was utilized according to instructions for the RNA isolation. For subsequent normalization synthetic Caenorhabditis elegans miR-39 (5 μl of 1 fmol/μl) was added as spike-in control during RNA isolation to the Qiazol/chloroform/plasma mixture [8].
Table 1. Patient groups.

|                  | Control | HF  | TTR  | SCA  |
|------------------|---------|-----|------|------|
| number           | 10      | 10  | 13   | 11   |
| age [y] ± SD     | 62.70 ± 6.45 | 70.50 ± 6.08 | 67.54 ± 8.31 | 78.45 ± 4.57 |
| gender           | f = 3; m = 7 | f = 0; m = 10 | f = 4; m = 9 | f = 0; m = 11 |

HF = heart failure; TTR = transthyretin; SCA = senile cardiac amyloidosis; y = years; SD = standard deviation; f = female; m = male

https://doi.org/10.1371/journal.pone.0204235.t001

TaqMan ArrayCard microRNA screening

For performing a microRNA expression profile isolated RNA of single individuals were pooled within their groups. After preamplification, TaqMan gene expression array cards—384-well microfluidic cards (ThermoFisher SCIENTIFIC) were used according to manufacturer’s instructions. 753 different reactions of microRNA were measured. For analyzing array data we used -ddCT method.

Validation of microRNA candidates using realtime PCR

TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) was used according to developer’s instructions to transcribe the isolated RNA of each blood sample to their complementary DNA (cDNA). For validation the microRNAs miR-99a-5p, miR-122-5p, miR-27a-3p, miR-221-3p, miR-1180-3p, miR-155-5p, miR-339-3p, miR-574-3p, miR-342-3p and miR-329-3p were chosen. By using TaqMan MicroRNA assays (Applied Biosystems) the microRNAs were amplified with quantitative realtime PCR (qrt-PCR). Afterwards expression results were normalized to cel-miR-39. qPCR was performed on a Viia7 Real-Time PCR system (Thermo Fisher Scientific) (15 min at 95˚C, 45 cycles of 15 sec at 95˚C and 1 min at 60˚C). The QuantStudioTM Real-Time PCR software (v1.1) was used to determine quantification cycle. Ct was defined as the fractional cycle number at which the fluorescence exceeded a given threshold. Relative quantification was performed using the 2-dCt method, where dCt = Ct[miRNA]—Ct[cel-miR-39].

Statistical analysis

For statistical analysis and graphical illustration of demographics and expression data GraphPad Prism 6 was utilized. For analyzing the regulation of miRNAs between the different

Table 2. Demographics.

|                  | HF        | TTR       | SCA       | HF vs. TTR vs. SCA |
|------------------|-----------|-----------|-----------|--------------------|
| BMI [kg/sq m] ± SD | 26.18 ± 2.46 | 27.42 ± 5.20 | 25.24 ± 4.13 | ns                 |
| Diabetes mellitus [%] | 50.00% (n = 5) | 15.38% (n = 2) | 27.27% (n = 2) | ns                 |
| LVEF [%] ± SD     | 26.00 ± 5.35 | 36.25 ± 16.67 | 41.18 ± 15.14 | ns                 |
| BNP [pg/ml] ± SD  | 341.4 ± 336.9 | 775.3 ± 821.6 | 818.4 ± 862.0 | ns                 |
| Hct [%] ± SD      | 39.59 ± 4.17 | 40.18 ± 5.01 | 39.27 ± 6.90 | ns                 |
| HDL [mg/dl] ± SD  | 37.33 ± 8.31 | 45.33 ± 16.67 | 51.33 ± 13.94 | ns                 |
| LDL [mg/dl] ± SD  | 73.22 ± 24.19 | 81.89 ± 41.75 | 82.17 ± 43.61 | ns                 |

HF = heart failure; TTR = transthyretin; SCA = senile cardiac amyloidosis; BMI = body mass index; LVEF = left ventricular ejection fraction; BNP = Brain natriuretic peptide; Hct = Haematocrit; ns = not significant; H/LDL = High/Low Density Protein

https://doi.org/10.1371/journal.pone.0204235.t002
patient groups and control based on Ct-values Kruskal-Wallis test (Nonparametric One-way ANOVA multi comparison test) were used. Graphs were illustrated as scatter plots with standard deviation. For array card analysis p-values < 0.05 defined significance using a two-sided t-test.

**Results**

**Clinical characteristics**

In this study, 10 controls, 10 heart failure patients, 13 TTR mutation patients and 11 senile cardiac amyloidosis patients were included. There were no statistical significant differences in age of controls, heart failure and TTR group but the patients affected with senile cardiac amyloidosis were significantly older than control and TTR group. Comparing the gender, in all groups more men than women were included (Table 1). There was no difference in BMI. In the heart failure group we included more patients with diabetes mellitus but this was without statistical significance. Comparing cholesterol, in particular LDL and HDL cholesterol, there was also no difference (Table 2).
MicroRNA-Array results

Comparing the control group to SCA patients, miR-329-3p, miR-342-3p, miR-339-3p and miR-99a-5p were significantly upregulated in SCA. In contrast, miR-27a-3p and miR-221-3p were decreased (Fig 1). When comparing the heart failure group with SCA group there was a significant upregulation of miR-574-3p, miR-501-5p, miR-99a-5p, miR-1227-3p, miR-151-3p, miR-1180-3p and miR-155-5p. Similar to the control group miR-122-5p was decreased as well as miR-27a-3p (Fig 2). Nevertheless, while comparing TTR group and SCA patients the microRNAs miR-342-3p, miR-574-3p, miR-99a-5p, miR-664-3p, miR-1180-3p, miR-1271-5p, miR-329-3p and miR-339-3p were significantly increased in SCA group. Whereas, miR-122-5p and miR-133a-3p were downregulated (Fig 3). Based on these results the microRNAs miR-99a-5p, miR-122-5p, miR-27a-3p, miR-221-3p, miR-1180-3p, miR-155-5p, miR-339-3p, miR-574-3p, miR-342-3p and miR-329-3p were chosen for validation.

Validation data

Looking at the validated microRNA selection, there was no dysregulation of the circulating miR-99a-5p and miR-122-5p between the different groups (Fig 4A and 4B). Beside it, the
The circulating expression of miR-27a was not increased in any group, but significantly decreased in TTR patients compared to control (Fig 4C). There were also no differences in circulating levels of the microRNAs miR-221-3p, miR-1180-3p, miR-155-5p and miR-342-3p (Fig 4D, 4E, 4F and 4G). In addition, levels of miR-339-3p were significantly increased in patients with senile cardiac amyloidosis whereas not in the other patient groups (Fig 5). Primer sequences of validated microRNAs are shown in Table 3.

**Discussion**

In this study, we performed a microRNA assay in samples derived from patients with different forms of cardiac amyloidosis and validated promising biomarker candidates to distinguish different forms of amyloidosis, heart failure patients as well as healthy individuals. Up to date, there is no other study showing the regulation of microRNAs in cardiac amyloidosis. In array profiling experiments, we found 10 candidates being deregulated in TTR amyloidosis and senile cardiac amyloidosis.
MicroRNA miR-99a, which was upregulated in array profiling in patients with SCA, was recently shown as tumor suppressor in lung cancer working together with oncogenic proteins EMR2 and E2F2 [9]. In validation experiments, this miRNA failed as possible biomarker for cardiac amyloidosis. Also, miR-574-3p and miR-329 was detected only in a very low number of patient samples. Moreover, miR-122, which was previously described as marker of neurological damage in blood of patients after cardiac arrest [10], did not show any significant regulation in patients with cardiac amyloidosis. Further, miR-155 also failed in our validation cohort as potential biomarker for cardiac amyloidosis. In heart diseases, miR-155 is described as a promoter of cardiac hypertrophy leading to heart failure [11]. Interestingly, we found that...
miR-339-3p was significantly upregulated in both array data and validation analysis compared to control samples. Until today, miR-339-3p has not been described as a specific circulating biomarker in any heart disease. There is also no previously reported association between miR-339-3p and amyloidosis. It is known that miR-339-3p functions as a suppressor in melanoma by targeting the oncogene MCL1 [12]. Besides melanoma, miR-339-3p is also described as inhibitor for colorectal cancer tumor growth in in-vitro experiments [13]. Thus, miR-339-3p was mainly known in the cancer field. However, our work suggests that miR-339-3p will be a promising candidate as clinical biomarker for senile cardiac amyloidosis. The exact pathophysiological mechanisms of the origin and secretion of miR-339-3p into the blood in cardiac amyloidosis remains unclear and needs to be explored in future studies. Although, miR-221 was described as promoter of cardiac hypertrophy [14], it was not dysregulated in our validation experiments. Also expression levels of miR-27a described e.g. as anti-hypertrophic in rat cardiomyocytes [15] and miR-1180-3p were not significantly dysregulated in any of our patient groups. Interestingly, miR-342-3p being described as decreased in acute heart failure did not show any dysregulation either in our heart failure group or in cardiac amyloidosis groups [16,17].

In this study are also limitations. The unbalanced age of the senile cardiac amyloidosis group is most likely due to the incidence of the disease in higher ages. Another limitation is the small sample size within the different groups owing to the relative rareness of cardiac amyloidosis and therefore the small patient population. In addition, our study did not reveal the pathomechanism behind the upregulation of miR-339-3p in patients with senile cardiac amyloidosis.

### Conclusion

In conclusion, miR-339-3p was increased in the plasma of patients with senile cardiac amyloidosis as identified by array profiling and validated by qPCR. Thus, miR-339-3p is a potential candidate biomarker for senile cardiac amyloidosis. Larger cohorts should be investigated in the future.

### Supporting information

S1 Array Supplement.
(XLSX)
Acknowledgments
We thank all the patients, who participated in this study.

Author Contributions
Conceptualization: P. Christian Schulze, Thomas Thum.
Data curation: Anselm A. Derda, Peter J. Kennel, Ke Xiao, P. Christian Schulze.
Formal analysis: Anselm A. Derda, Christian Bär, Ke Xiao.
Funding acquisition: Johann Bauersachs, Thomas Thum.
Investigation: Anselm A. Derda, P. Christian Schulze, Johann Bauersachs, Thomas Thum.
Methodology: Anselm A. Derda, Angelika Pfanne, Christian Bär, Katharina Schimmel, Thomas Thum.
Project administration: Thomas Thum.
Resources: P. Christian Schulze, Thomas Thum.
Supervision: Johann Bauersachs, Thomas Thum.
Validation: Anselm A. Derda.
Visualization: Anselm A. Derda, Ke Xiao.
Writing – original draft: Anselm A. Derda.
Writing – review & editing: P. Christian Schulze, Johann Bauersachs, Thomas Thum.

References
1. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004; 103: 2936–2938. https://doi.org/10.1182/blood-2003-08-2788 PMID: 15070667
2. Hoyer C, Angermann CE, Knop S, Ertl G, Stork S. Cardiac amyloidosis. Med Klin (Munich). 2008; 103: 153–160.
3. Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015; 278: 126–144. https://doi.org/10.1111/joim.12383 PMID: 26077367
4. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112: 2047–2060. https://doi.org/10.1161/CIRCULATIONAHA.104.489187 PMID: 16186440
5. Bauersachs J, Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res. 2011; 109: 334–347. https://doi.org/10.1161/CIRCRESAHA.110.228676 PMID: 21778437
6. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456: 980–984. https://doi.org/10.1038/nature07511 PMID: 19043405
7. Jaguszewski M, Osipova J, Ghadri JR, Napp LC, Widera C, Franke J, et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J. 2014; 35: 999–1006. https://doi.org/10.1093/eurheartj/ehu215 PMID: 24046434
8. Derda AA, Thum S, Lorenzen JM, Bavendiek U, Heineke J, Keyser B, et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol. 2015; 196: 115–122. https://doi.org/10.1016/j.ijcard.2015.06.185 PMID: 26086795
9. Feliciano A, Garcia-Mayeza Y, Jubierre L, Mir C, Hummel M, Castelviri J, et al. miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer. Cell Death Dis. 2017; 8: e3141. https://doi.org/10.1038/cddis.2017.54 PMID: 29072692
10. Stammet P, Goretti E, Vausort M, Zhang L, Wagner DR, Devaux Y. Circulating microRNAs after cardiac arrest. Crit Care Med. 2012; 40: 3209–3214. https://doi.org/10.1097/CCM.0b013e318251dd5e PMID: 22890253
11. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013; 128: 1420–1432. https://doi.org/10.1161/CIRCULATIONAHA.112.001357 PMID: 23956210

12. Weber CE, Luo C, Hotz-Wagenblatt A, Gardyan A, Kordass T, Holland-Letz T, et al. miR-339-3p is a Tumor Suppressor in Melanoma. Cancer Res. 2016; 76: 3562–3571. https://doi.org/10.1158/0008-5472.CAN-15-2932 PMID: 27197185

13. Zhou C, Lu Y, Li X. miR-339-3p inhibits proliferation and metastasis of colorectal cancer. Oncol Lett. 2015; 10: 2842–2848. https://doi.org/10.3892/ol.2015.3661 PMID: 26722251

14. Wang C, Wang S, Zhao P, Wang X, Wang J, Wang Y, et al. MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression. J Cell Biochem. 2012; 113: 2040–2046. https://doi.org/10.1002/jcb.24075 PMID: 22275134

15. Jentzsch C, Leierseder S, Loyer X, Flohrschutz I, Sassi Y, Hartmann D, et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol. 2012; 52: 13–20. https://doi.org/10.1016/j.yjmcc.2011.07.010 PMID: 21801730

16. Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail. 2013; 15: 1138–1147. https://doi.org/10.1093/eurjhf/hft078 PMID: 23696613

17. Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016; 18: 457–468. https://doi.org/10.1002/ejhf.495 PMID: 26869172